StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.56+0.06 (+0.29%)

Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%

Damora Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Damora Therapeutics's total assets was $532.63M at Sep 30, 2026. For fiscal 2025 it was $260.53M, up 1420.7% from the year before. The highest annual figure on record is $260.53M in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$260.53M+1420.7%
FY2024Dec 31, 2024$17.13M-55.2%
FY2023Dec 31, 2023$38.23M-47.8%
FY2022Dec 31, 2022$73.19M-40.1%
FY2021Dec 31, 2021$122.22M-28.8%
FY2020Dec 31, 2020$171.60M+203.1%
FY2019Dec 31, 2019$56.61M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$532.63M+4861.1%
Q2 FY2026Jun 30, 2026$543.64M+3870.8%
Q1 FY2026Mar 31, 2026$535.44M+3384.8%
Q4 FY2025Dec 31, 2025$260.53M+1420.7%
Q3 FY2025Sep 30, 2025$10.74M-54.1%
Q2 FY2025Jun 30, 2025$13.69M-49.8%
Q1 FY2025Mar 31, 2025$15.37M-52.7%
Q4 FY2024Dec 31, 2024$17.13M-55.2%
Q3 FY2024Sep 30, 2024$23.38M-53.3%
Q2 FY2024Jun 30, 2024$27.30M-53.6%
Q1 FY2024Mar 31, 2024$32.48M-49.7%
Q4 FY2023Dec 31, 2023$38.23M-47.8%
Q3 FY2023Sep 30, 2023$50.05M-39.0%
Q2 FY2023Jun 30, 2023$58.80M-36.7%
Q1 FY2023Mar 31, 2023$64.63M-40.7%
Q4 FY2022Dec 31, 2022$73.19M-40.1%
Q3 FY2022Sep 30, 2022$82.03M-39.6%
Q2 FY2022Jun 30, 2022$92.86M-36.8%
Q1 FY2022Mar 31, 2022$108.93M-31.3%
Q4 FY2021Dec 31, 2021$122.22M-28.8%
Q3 FY2021Sep 30, 2021$135.87M+38.4%
Q2 FY2021Jun 30, 2021$146.82M+159.4%
Q1 FY2021Mar 31, 2021$158.66M–
Q4 FY2020Dec 31, 2020$171.60M–
Q3 FY2020Sep 30, 2020$98.15M–
Q4 FY2019Dec 31, 2019$56.61M–

More Damora Therapeutics figures

See a number that looks wrong?